CELSION CORPORATION ANNOUNCES ADJOURNMENT OF ANNUAL MEETING
04 juin 2021 10h11 HE
|
Celsion CORP
49% of Shares Voted, Quorum Not Established To Hold Annual Meeting Polls Remain Open Stockholders Holding Unvoted Proxies Are Strongly Encouraged to Vote Their Shares LAWRENCEVILLE, N.J.,...
Phase 2b VITAL study of Gemogenovatucel-T (Vigil™) immunotherapy demonstrates clinical benefit in homologous recombination (HR) proficient ovarian cancer
26 mars 2021 11h41 HE
|
Gradalis, Inc.
Results from pre-planned subgroup analysis of stage III/IV newly diagnosed ovarian cancer patients with BRCA wild type (BRCA-wt) profile and homologous recombination proficiency (HRP) have been...
Gradalis Announces Publication of Phase 2b VITAL trial of Vigil® demonstrating RFS and OS advantage in women with first-line platinum-responsive BRCA1 and BRCA2 wild-type advanced ovarian cancer in The Lancet Oncology
07 janv. 2021 07h00 HE
|
Gradalis, Inc.
The VITAL study, published in The Lancet Oncology, demonstrates that Vigil first-line maintenance treatment resulted in improved RFS in BRCA1/2-wt ovarian cancer when compared to placebo.Importantly...
Global $136.7 Billion Oncology Market to 2025
30 oct. 2020 03h13 HE
|
Research and Markets
Dublin, Oct. 30, 2020 (GLOBE NEWSWIRE) -- The "Oncology Market - Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering. Oncology Market size was valued at $136.7...
THE NATIONAL OVARIAN CANCER COALITION TO HOST ITS ANNUAL TOGETHER IN TEAL® - NO BOUNDARIES NATIONAL BROADCAST CELEBRATION DURING SEPTEMBER AWARENESS MONTH ON SATURDAY, SEPTEMBER 26, 2020
28 août 2020 11h00 HE
|
National Ovarian Cancer Coalition
Dallas, Texas, Aug. 28, 2020 (GLOBE NEWSWIRE) -- DALLAS, TX August 28, 2020 —September is National Ovarian Cancer Awareness Month. The National Ovarian Cancer Coalition (NOCC) is tirelessly working...
Aravive Announces AVB-500 Improves Anti-Tumor Effects when Combined with Anti-Angiogenic Bevacizumab or PARP Inhibitor Olaparib in Preclinical Models of Uterine Cancer
30 mars 2020 08h00 HE
|
Aravive, Inc.
Inhibition of GAS6/AXL signaling induces ‘BRCAness’ in preclinical model of ovarian cancer, increasing response to platinum chemotherapy and PARP inhibitor Multiple Abstracts Published on Website of...
Aravive Announces Dose Escalation of AVB-500 in Recurrent Platinum Resistant Ovarian Cancer Phase 1b Trial
18 févr. 2020 08h00 HE
|
Aravive, Inc.
Dose escalation of AVB-500 to 20mg/kg dose follows positive recommendation by independent Data Monitoring Committee review Plan to initiate Phase 2/3 study in Platinum Resistant Ovarian Cancer by...
Predictive Oncology Featured in Broadcast Evaluating Targeted Cancer Therapies, Higher Survival Rates
07 nov. 2019 08h30 HE
|
Predictive Oncology
NEW YORK, Nov. 07, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – Predictive Oncology (NASDAQ: POAI) announces the availability of a broadcast titled, “New Hope in the Battle Against Ovarian...
Predictive Oncology Featured in Publication Discussing the Impact of Artificial Intelligence on Cancer Treatment
06 nov. 2019 08h30 HE
|
Predictive Oncology
NEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) -- via NetworkWire — Predictive Oncology (NASDAQ: POAI) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted...
Celsion Announces DSMB Recommendation to Continue GEN-1 at 100mg/m² Dose to Complete the Phase I Portion of OVATION 2 Study in Ovarian Cancer
05 nov. 2019 08h00 HE
|
Celsion CORP
GEN-1 Manufacturing Technology Transfer Successfully Produces High-Quality Affordable Investigational Product for Use in Clinical Trials LAWRENCEVILLE, N.J., Nov. 05, 2019 (GLOBE NEWSWIRE) --...